International Journal of Hematology and Oncology 2022, Vol 32, Num 2 (Special Issue) Page(s): 003-009
Paradigm Shift in Metastatic Malignant Melanoma


Gaziantep University, Faculty of Medicine, Department of Medical Oncology, Gaziantep, TURKEY

Keywords: Metastatic melanoma, Ipilimumab, Vemurafenib, Paradigm
Substantial advancements have been made in the treatment of metastatic malignant melanoma, for which therapeutic options were quite limited until recently, with the elucidation of molecular pathways that play role in the development and progression of the disease. Although remarkable improvement has been achieved in survival rates with these advancements, a satisfactory response rate could not be obtained or high response rates could not be maintained. In this paper, therapeutic options for metastatic melanoma, particularly ipilimumab and vemurafenib that are also in use in our country, were summarized.